<DOC>
	<DOC>NCT02627261</DOC>
	<brief_summary>Three methods including flow cytometry, next generation sequencing and determination of circulating tumor cells will be performed at different time points in patients with previously undiagnosed multiple myeloma in order to determine the most sensitive method to detect residual disease</brief_summary>
	<brief_title>Multiple Myeloma Minimal Residual Disease</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<criteria>â‰¥ 18 years previously undiagnosed myeloma eligible for high dose therapy and bone marrow transplantation signed consent ongoing therapy for another neoplasia Patients with other hematologic malignancies, patients deprived of liberty for administrative or judicial reasons previously treated for myeloma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>residual disease</keyword>
</DOC>